Nasdaq:US$20.17 (-0.79) | HKEX:HK$32.05 (+0.35) | AIM:£3.20 (-0.04)
搜索結果
上一篇文章   |   下一篇文章
公告及新聞稿, 腫瘤學 / 免疫學 | 2009-02-17

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate